

## FILGOTINIB tablets (Jyseleca® ▼) for treating moderately to severely active ulcerative colitis

**The Pan Mersey Area Prescribing Committee recommends the prescribing of FILGOTINIB tablets (Jyseleca® ▼), by specialists only, for treating moderately to severely active ulcerative colitis in accordance with NICE TA792.**

**RED**

[NICE technology appraisal \(TA\) 792](#) recommends filgotinib, within its marketing authorisation, as an option for treating moderately to severely active ulcerative colitis in adults:

- > when conventional or biological treatment cannot be tolerated, **or**
- > if the disease has not responded well enough or has stopped responding to these treatments, **and**
- > if the company provides filgotinib according to the commercial arrangement.<sup>1</sup>

Prescribing should be retained by a specialist in the treatment of ulcerative colitis.

### Costing information

The average cost for each patient per year is estimated at £10,508 based on the NHS list price. The company has a commercial arrangement that makes filgotinib available to the NHS with a discount.<sup>1</sup>

NICE does not expect this guidance to have a significant impact on resources; that is, the resource impact of implementing the recommendations in England will be less than £5 million per year (or £9,000 per 100,000 population). This is because filgotinib is a further treatment option and the overall cost of treatment will be comparable to the current treatment options available.<sup>2</sup>

### References

1. National Institute for Health and Care Excellence. Technology appraisal guidance 792: [Filgotinib for treating moderately to severely active ulcerative colitis](#), 01 June 2022. Accessed 09 June 2022.
2. National Institute for Health and Care Excellence. Technology appraisal guidance 792: [Resource impact statement, Filgotinib for treating moderately to severely active ulcerative colitis](#), 01 June 2022. Accessed 09 June 2022.

**Note:** Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.